On the stock market since 1980, it operates in the world of health and science. It has 873 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 9% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades below its recent peak — about 11% off the top. A pullback, not a collapse.
Sales run at $125.2M a year. A small number, but proof the product has real buyers.
There is $25.0M in the vault; even if every debt were paid off, $19.8M would remain.
It pays out $1.92 per share each year — regular cash for whoever holds the stock.
A loss of $64K against $125.2M in annual sales.
The price action doesn’t yet back an upward turn. Council score: 0/10.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
On our five-subject report card, IIN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: IIN is a high-risk stock — not yet profitable, and its future rides on its product catching on.